Nam D. Nguyen, DO (Maj., USAF, MC), Erica Hill, DO (Lt. Col., USAF, MC), & Jay Higgs, MD (Col. [ret], USAF, MC) | Issue: November 2021 |
WASHINGTON, D.C.—As treatments for rheumatoid arthritis (RA) improve, some related conditions that used to be common in patients with RA are not seen very often anymore, but they still exist and physicians need to know how to identify them. Speaking to attendees at the ACR/ARHP Annual Meeting talk titled Rheumatoid Arthritis—A Case-Based Approach to Selected…
ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…
Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.
MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS